Eden Research plc held its Annual General Meeting, where Chairman Lykele van der Broek highlighted the company's significant progress in achieving strategic growth objectives and value creation. The 2023 financial results showed a 78% revenue growth, driven by the successful launch of the bird repellent seed treatment product, Ecovelex™. The company is awaiting full regulatory authorization for Ecovelex in various countries, including the EU and the UK, and is also exploring new markets and uses for the product.

The growth strategy for other flagship products, Mevalone® and Cedroz™, has been successful, particularly with regulatory approvals in various US states. The company also reported positive results from field trials for its insecticide product, indicating promising developments in a market facing increasing scrutiny for environmental impact.

Eden Research successfully completed a fundraise, providing the financial resources needed to accelerate workstreams, increase development capacity, and expand the commercial team. The company welcomed new investors and expressed gratitude to existing shareholders for their unwavering support. The addition of new members to the commercial team is expected to drive revenue growth through both existing business expansion and pursuit of new opportunities.

The company also announced the appointment of Derek McAllan as Non-Executive Director, bringing considerable experience in advising growth companies. The Board expressed gratitude to investors and the Eden team for their support and hard work, emphasizing the company's positive growth trajectory and the importance of maintaining resources to realize its full value.

For further information, contact Eden Research plc or visit their website. Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture, developing and supplying innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health, and consumer products industries.